etoposide phosphate and Recrudescence

etoposide phosphate has been researched along with Recrudescence in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cirillo, M; O'Sullivan, M; Polistena, P; Purtill, D; Tran, Q	1
Doolittle, ND; Kraemer, DF; Lacy, C; Neutwelt, EA; Siegal, T; Tyson, RM	1
Braybrooke, JP; Davies, SL; Echeta, C; Flanagan, E; Ganesan, TS; Hickson, ID; Joel, S; Levitt, NC; Madhusudan, S; Propper, DJ; Te Poele, R	1

Trials

1 trial(s) available for etoposide phosphate and Recrudescence

Article	Year
Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. British journal of cancer, 2005, Jul-11, Volume: 93, Issue:1 Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Middle Aged; Organophosphorus Compounds; Ovarian Neoplasms; Quality of Life; Recurrence; Topotecan	2005

Article

Year

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.

British journal of cancer, 2005, Jul-11, Volume: 93, Issue:1

Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Middle Aged; Organophosphorus Compounds; Ovarian Neoplasms; Quality of Life; Recurrence; Topotecan

2005

Other Studies

2 other study(ies) available for etoposide phosphate and Recrudescence

Article	Year
Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma. Bone marrow transplantation, 2017, Volume: 52, Issue:3 Topics: Adult; Desensitization, Immunologic; Drug Hypersensitivity; Etoposide; Hodgkin Disease; Humans; Male; Organophosphorus Compounds; Recurrence	2017
Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leukemia & lymphoma, 2003, Volume: 44, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Organophosphorus Compounds; Radioimmunotherapy; Recurrence; Rituximab; Time Factors	2003

Article

Year

Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma.

Bone marrow transplantation, 2017, Volume: 52, Issue:3

Topics: Adult; Desensitization, Immunologic; Drug Hypersensitivity; Etoposide; Hodgkin Disease; Humans; Male; Organophosphorus Compounds; Recurrence

2017

Current status and future of relapsed primary central nervous system lymphoma (PCNSL).

Leukemia & lymphoma, 2003, Volume: 44, Issue:4

Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Organophosphorus Compounds; Radioimmunotherapy; Recurrence; Rituximab; Time Factors

2003